The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 11, 2013, Pages

  Thosani, Sonali ^a   Ayala Ramirez, Montserrat ^a   Palmer, Lynn ^a   Hu, Mimi I ^a   Rich, Thereasa ^a   Gagel, Robert F ^a   Cote, Gilbert ^a   Waguespack, Steven G ^a   Habra, Mouhammed Amir ^a   Jimenez, Camilo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENE; GENE MUTATION; GENETIC CODE; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS POTENTIAL; MULTIPLE ENDOCRINE NEOPLASIA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2; NEUROFIBROMATOSIS; OVERALL SURVIVAL; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RET GENE; SIPPLE SYNDROME; SURVIVAL RATE; SURVIVAL TIME; THYROID MEDULLARY CARCINOMA; TUMOR VOLUME;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGE OF ONSET; CHILD; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MUTATION, MISSENSE; PHEOCHROMOCYTOMA; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-RET; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84887458723     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1653     Document Type: Article

References (22)

1. Toledo SP, dos SantosMA,Toledo Rde A, LourencoDM,Jr. Impact of RET proto-oncogene analysis on the clinical management of multiple endocrine neoplasia type 2. Clinics (Sao Paulo). 2006;61(1): 59-70.
2. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276(19): 1575-1579.
3. Mulligan LM, Eng C, Healey CS, et al. Specific mutations of theRET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet. 1994;6(1): 70-74.
4. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001; 86(12): 5658-5671.
5. Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19(6): 565-612.
6. Bryant J, Farmer J, Kessler LJ, Townsend RR, Nathanson KL. Pheochromocytoma: the expanding genetic differential diagnosis. J Natl Cancer Inst. 2003;95(16): 1196-1204.
7. Ayala-Ramirez M, Feng L, Johnson MM, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011;96(3): 717-725.
8. Quayle FJ, Fialkowski EA, Benveniste R, Moley JF. Pheochromocytoma penetrance varies by RET mutation in MEN 2A. Surgery. 2007;142(6):800-805; discussion 805.e1.
9. Nguyen L, Niccoli-Sire P, Caron P, et al. Pheochromocytoma in multiple endocrine neoplasia type 2: a prospective study. Eur J Endocrinol. 2001;144(1): 37-44.
10. Machens A, Brauckhoff M, Holzhausen HJ, Thanh PN, Lehnert H, Dralle H. Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 2005; 90(7): 3999-4003.
11. Erlic Z, Neumann HP. When should genetic testing be obtained in a patient with phaeochromocytoma or paraganglioma? Clin Endocrinol (Oxf),. 2009;70(3): 354-347.
12. Pomares FJ, Canas R, Rodriguez JM, Hernandez AM, Parrilla P, Tebar FJ. Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma. Clin Endocrinol (Oxf). 1998; 48(2): 195-200.
13. Waguespack SG, Rich T, Grubbs E, Ying AK, Perrier ND, Ayala- Ramirez M, Jimenez C. A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2010;95(5): 2023-2037.
14. Benn DE, Robinson BG. Genetic basis of phaeochromocytoma and paraganglioma. Best Pract Res Clin Endocrinol Metab. 2006;20(3): 435-450.
15. Machens A, Brauckhoff M, Gimm O, Dralle H. Risk-oriented approach to hereditary adrenal pheochromocytoma. Ann N Y Acad Sci. 2006;1073: 417-428.
16. Eisenhofer G, Lenders JW, Timmers H, et al. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem. 2011;57(3): 411-420.
17. Jimenez C, Cote G, Arnold A, Gagel RF. Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? J Clin Endocrinol Metab. 2006;91(8): 2851-2858.
18. Raue F, Frank-Raue K, Grauer A. Multiple endocrine neoplasia type 2. Clinical features and screening. Endocrinol Metab Clin North Am. 1994;23(1): 137-156.
19. Brunt LM, Lairmore TC, Doherty GM, Quasebarth MA, DeBenedetti M, Moley JF. Adrenalectomy for familial pheochromocytoma in the laparoscopic era.AnnSurg. 2002;235(5):713-720; discussion 720-721.
20. Lairmore TC, Ball DW, Baylin SB, Wells SA, Jr. Management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes. Ann Surg. 1993;217(6):595-601; discussion 601-603.
21. Machens A, Lorenz K, Dralle H. Peak incidence of pheochromocytoma and primary hyperparathyroidism in multiple endocrine neoplasia 2: need for age-adjusted biochemical screening. J Clin Endocrinol Metab. 2013;98(2):E336-E345.
22. Rodriguez JM, Balsalobre M, Ponce JL, Rios A, Torregrosa NM, Tebar J, Parrilla P. Pheochromocytoma in MEN 2A syndrome. study of 54 patients. World J Surg. 2008;32(11): 2520-2526.